A Quarter Century of Thalidomide Embryopathy

Thalidomide Embryopathy: An Enigmatic Challenge

Thalidomide remains one of the world’s most notorious drugs due to the severe birth defects it induced in children between 1957 and 1962. Yet, to some this drug is a lifesaver, as it now enjoys renaissance in the treatment for a wide range of conditions including leprosy, multiple myeloma, Behcet’s disease, and some cancers. However, thalidomide has also been linked to causing a new generation ...

New cases of thalidomide embryopathy in Brazil.

Thalidomide is the best known human teratogen. Although withdrawn from the market in 1961, thalidomide was remarketed after 1965 in several countries, for the treatment of erythema nodosum leprosum. Thalidomide has a potent immunomodulatory property and has now a number of approved and off-label uses in dermatologic, oncologic, infectious and gastrointestinal conditions. In the U.S., FDA approv...

A Quarter Century of Glycobiology.

As was pointed out in the editorial in the very first issue ofGlycobiology (Hart 1990), the study of the biology of carbohydrates and glycoconjugates dates back to the earliest foundations of biochemistry. What is now the Society for Glycobiology dates back to small meetings organized by the founding fathers of our field, which took place in the early 1960s (for a historical review, see Silbert...

A quarter of a century with Iranian Journal of Nuclear Medicine

ENDOCRINOLOGY AND METABOLISM INSTITUTE OVER TIME: A QUARTER OF A CENTURY OF EXPERIENCE

Endocrinology and Metabolism Research Institute (EMRI) was established in 1993. EMRI has progressed step by step from the beginning and has reached maturity in the last 25 years. EMRI has expanded, advanced in human resources and infrastructures (laboratories and new technologies) and gained first rank in endocrine research in various fields. It has also worked with regional and international o...